The British journal of radiology · 2026
Prediction of upgrading in clinically insignificant prostate cancer patients undergoing radical prostatectomy: the value of Ga-68-PSMA PET/CT.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Özbilen Mert Hamza, Karaca Erkin, Sağmak Burak, Kök Yusuf Enes, Çakıcı Mehmet Çağlar, Polat Kelle Aygül, Kısa Erdem, Koç Gökhan, Erçil Hakan
Аннотация
OBJECTIVES: To evaluate the role of clinical and pathological variables, multiparametric magnetic resonance imaging (mpMRI), and Ga-68-PSMA PET/CT in prediction upgrading in patients who underwent radical prostatectomy (RP) for clinically insignificant prostate cancer (ciPCa).
METHODS: Patients with The International Society of Urological Pathology (ISUP) grade group(GG) 1 by biopsy (bISUP GG 1) who underwent Ga-68-PSMA PET were reviewed. 38 who did not upgrade after RP were defined as group 1, and 37 who were upgraded after RP were defined as group 2.
RESULTS: In patients with bISUP GG 1, the upgrade detection rate of the ISUP GG on RP material was 49.3%. PI-RADS 3, 4, and 5 scores were 71.1%, 18.4%, and 2.6% in group 1, respectively, whereas 51.4%, 18.9%, and 29.7% in group 2, respectively (p = 0.002). Mean index lesion diameter on mpMRI (p = 0.007) were found to be higher in patients who upgraded. The SUVmax detected on Ga-68-PSMA PET/CT was 4.65 in group 1 and 7 in group 2 (p = 0.003). ROC curve analysis provided a cut-off value of 4.6 g/mL for the SUVmax that would predict upgrading. PI-RADS 4-5 lesions on mpMRI (OR: 3.354, 95% CI: 1.124-10.007, p = 0.030) and SUVmax ≥ 4.6 on PSMA PET/CT (OR: 6.113, 95%CI: 1.893-19.875, p = 0.002) were found to be predictors for upgrading in multivariate analysis.
CONCLUSIONS: Ga-68-PSMA PET/CT was found to be a potentially useful imaging biomarker for predicting pathological upgrading from combined systematic biopsy and mpMRI- targeted biopsy to RP.
ADVANCES IN KNOWLEDGE: For patients with ciPCa, there is a high likelihood of risk reclassification if they have PI-RADS 4-5 score and SUVmax higher than 4.6 on Ga-68-PSMA PET/CT.
METHODS: Patients with The International Society of Urological Pathology (ISUP) grade group(GG) 1 by biopsy (bISUP GG 1) who underwent Ga-68-PSMA PET were reviewed. 38 who did not upgrade after RP were defined as group 1, and 37 who were upgraded after RP were defined as group 2.
RESULTS: In patients with bISUP GG 1, the upgrade detection rate of the ISUP GG on RP material was 49.3%. PI-RADS 3, 4, and 5 scores were 71.1%, 18.4%, and 2.6% in group 1, respectively, whereas 51.4%, 18.9%, and 29.7% in group 2, respectively (p = 0.002). Mean index lesion diameter on mpMRI (p = 0.007) were found to be higher in patients who upgraded. The SUVmax detected on Ga-68-PSMA PET/CT was 4.65 in group 1 and 7 in group 2 (p = 0.003). ROC curve analysis provided a cut-off value of 4.6 g/mL for the SUVmax that would predict upgrading. PI-RADS 4-5 lesions on mpMRI (OR: 3.354, 95% CI: 1.124-10.007, p = 0.030) and SUVmax ≥ 4.6 on PSMA PET/CT (OR: 6.113, 95%CI: 1.893-19.875, p = 0.002) were found to be predictors for upgrading in multivariate analysis.
CONCLUSIONS: Ga-68-PSMA PET/CT was found to be a potentially useful imaging biomarker for predicting pathological upgrading from combined systematic biopsy and mpMRI- targeted biopsy to RP.
ADVANCES IN KNOWLEDGE: For patients with ciPCa, there is a high likelihood of risk reclassification if they have PI-RADS 4-5 score and SUVmax higher than 4.6 on Ga-68-PSMA PET/CT.